Irmina Diala

832 total citations
21 papers, 373 citations indexed

About

Irmina Diala is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Irmina Diala has authored 21 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Irmina Diala's work include HER2/EGFR in Cancer Research (10 papers), Advanced Breast Cancer Therapies (8 papers) and Advanced biosensing and bioanalysis techniques (5 papers). Irmina Diala is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Advanced Breast Cancer Therapies (8 papers) and Advanced biosensing and bioanalysis techniques (5 papers). Irmina Diala collaborates with scholars based in United States, Japan and Ireland. Irmina Diala's co-authors include Alshad S. Lalani, Delphine Mérino, Sherene Loi, Steven David, Yvonne E. Smith, Robin L. Anderson, Delphine Denoyer, Scott Ayton, Normand Pouliot and Richard P. Redvers and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Irmina Diala

20 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Irmina Diala United States 9 200 168 147 97 50 21 373
Cristina Bernadó Morales Spain 9 144 0.7× 42 0.3× 163 1.1× 56 0.6× 49 1.0× 14 322
Pier‐Luc Clermont Canada 10 360 1.8× 169 1.0× 65 0.4× 154 1.6× 11 0.2× 15 477
Janét Pittsenbarger United States 6 245 1.2× 98 0.6× 101 0.7× 134 1.4× 20 0.4× 11 389
Elizabeth Moskatel United States 3 318 1.6× 57 0.3× 96 0.7× 44 0.5× 15 0.3× 4 389
Barbara Antoniani Italy 13 327 1.6× 66 0.4× 143 1.0× 135 1.4× 22 0.4× 20 463
Julius Semenas Sweden 9 235 1.2× 166 1.0× 89 0.6× 114 1.2× 9 0.2× 14 381
Meghan M. Morrison United States 7 185 0.9× 36 0.2× 171 1.2× 69 0.7× 52 1.0× 8 380
K. Takenaka Japan 10 152 0.8× 176 1.0× 116 0.8× 55 0.6× 41 0.8× 12 385
Wai Wong United States 4 284 1.4× 58 0.3× 71 0.5× 44 0.5× 26 0.5× 5 365

Countries citing papers authored by Irmina Diala

Since Specialization
Citations

This map shows the geographic impact of Irmina Diala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irmina Diala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irmina Diala more than expected).

Fields of papers citing papers by Irmina Diala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irmina Diala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irmina Diala. The network helps show where Irmina Diala may publish in the future.

Co-authorship network of co-authors of Irmina Diala

This figure shows the co-authorship network connecting the top 25 collaborators of Irmina Diala. A scholar is included among the top collaborators of Irmina Diala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irmina Diala. Irmina Diala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Conlon, Neil T., Naomi Walsh, Irmina Diala, et al.. (2022). Abstract P2-13-36: Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model. Cancer Research. 82(4_Supplement). P2–13. 1 indexed citations
2.
3.
4.
Conlon, Neil T., Suzanne J.C. van Gerwen, Guido J.R. Zaman, et al.. (2021). Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. British Journal of Cancer. 124(7). 1249–1259. 39 indexed citations
5.
Zhao, Ming, Kurt W. Evans, Erkan Yuca, et al.. (2021). Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clinical Cancer Research. 27(6). 1681–1694. 44 indexed citations
6.
Lee, Jangsoon, Toshiaki Iwase, Alshad S. Lalani, et al.. (2021). PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines. 9(7). 740–740. 11 indexed citations
7.
Veeraraghavan, Jamunarani, Sarmistha Nanda, Vidyalakshmi Sethunath, et al.. (2021). Abstract 1077: Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models. Cancer Research. 81(13_Supplement). 1077–1077. 1 indexed citations
8.
Bose, Ron, Shunqiang Li, Tina Primeau, et al.. (2021). Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan. Cancer Research. 81(4_Supplement). PS4–13. 5 indexed citations
9.
Redvers, Richard P., Scott Ayton, Irmina Diala, et al.. (2019). Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Research. 21(1). 94–94. 122 indexed citations
10.
11.
Ni, Jing, Yanzhi Wang, Irmina Diala, et al.. (2019). THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES. Neuro-Oncology Advances. 1(Supplement_1). i13–i13. 1 indexed citations
12.
Wang, Yanzhi, Irmina Diala, Sheheryar Kabraji, et al.. (2019). Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases. Cancer Research. 79(13_Supplement). 4832–4832. 3 indexed citations
13.
Booth, Laurence, Jane L. Roberts, Richard E. Cutler, et al.. (2018). Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition. Cancer Biology & Therapy. 20(2). 157–168. 8 indexed citations
14.
Booth, Laurence, Jane L. Roberts, Richard E. Cutler, et al.. (2018). Neratinib augments the lethality of [regorafenib + sildenafil]. Journal of Cellular Physiology. 234(4). 4874–4887. 29 indexed citations
15.
Sato, Shinobu, et al.. (2015). Screening for Oral Cancer Using Electrochemical Telomerase Assay. Electroanalysis. 28(3). 503–507. 11 indexed citations
16.
Diala, Irmina, Shinobu Sato, Michihiko Usui, et al.. (2013). Development of a Membrane-based Microwave-mediated Electrochemical ELISA Method for TNF-α Detection in Patients with Periodontitis. Analytical Sciences. 29(9). 927–930. 8 indexed citations
17.
Diala, Irmina, Nicole Wagner, Frédérique Magdinier, et al.. (2013). Telomere protection and TRF2 expression are enhanced by the canonical Wnt signalling pathway. EMBO Reports. 14(4). 356–363. 65 indexed citations
18.
Murao, Satoshi, et al.. (2008). Suppression of bcr-abl mRNA by Chemically Modified siRNA. Nucleic Acids Symposium Series. 52(1). 499–500. 1 indexed citations
19.
Diala, Irmina, Satoshi Murao, & Masayuki Fujii. (2008). Antisense Inhibition of Human Telomerase by Phosphorothioate Oligonucleotide-Peptide Conjugates. Nucleic Acids Symposium Series. 52(1). 679–680. 2 indexed citations
20.
Diala, Irmina, et al.. (2007). Synthesis of phosphorothioate oligonucleotide–peptide conjugates by solid phase fragment condensation. Bioorganic & Medicinal Chemistry Letters. 17(23). 6576–6578. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Bernadó Morales Breakdown of academic impact, for papers by Pier‐Luc Clermont Breakdown of academic impact, for papers by Janét Pittsenbarger Breakdown of academic impact, for papers by Elizabeth Moskatel Breakdown of academic impact, for papers by Barbara Antoniani Breakdown of academic impact, for papers by Julius Semenas Breakdown of academic impact, for papers by Meghan M. Morrison Breakdown of academic impact, for papers by K. Takenaka Breakdown of academic impact, for papers by Wai Wong
Rankless by CCL
2026